Janssen Announces European Commission Approval of JULUCA®▼ (dolutegravir/rilpivirine), the First Two-Drug Regimen, OnceDaily, Single-Pill for the Treatment of HIV-1
- EMEA Innovative Medicine
- Janssen Announces European Commission Approval of JULUCA®▼ (dolutegravir/rilpivirine), the First Two-Drug Regimen, OnceDaily, Single-Pill for the Treatment of HIV-1
Janssen Announces European Commission Approval of JULUCA®▼ (dolutegravir/rilpivirine), the First Two-Drug Regimen, OnceDaily, Single-Pill for the Treatment of HIV-1
- X (Twitter)
Copy link